Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: A substudy of AGELESS

Vascular Health and Risk Management

Volumn 10, Issue , 2014, Pages 389-397

  Baschiera, Fabio ^a   Chang, William ^a   Brunel, Patrick ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aliskiren; Central aortic pressure; Elderly; Ramipril; Systolic hypertension

Indexed keywords

ALISKIREN; AMLODIPINE; HYDROCHLOROTHIAZIDE; RAMIPRIL; AMIDE; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUMARIC ACID DERIVATIVE;

ADD ON THERAPY; AGED; ANTIHYPERTENSIVE ACTIVITY; AORTA PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CENTRAL AORTIC BLOOD PRESSURE; CENTRAL AORTIC DIASTOLIC BLOOD PRESSURE; CENTRAL AORTIC SYSTOLIC BLOOD PRESSURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PARALLEL DESIGN; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC HYPERTENSION; TREND STUDY; AORTA; ARTERIAL PRESSURE; COMPARATIVE STUDY; DRUG EFFECTS; HYPERTENSION; PATHOPHYSIOLOGY; SYSTOLE; TIME; TREATMENT OUTCOME;

AGED; AMIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; AORTA; ARTERIAL PRESSURE; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; RAMIPRIL; SYSTOLE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903789734     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S63725     Document Type: Article

References (36)

1. Vidt DG, Basile JN. Hypertension curriculum review. The importance of systolic blood pressure elevation in elderly persons. J Clin Hypertens (Greenwich). 2004;6(8):461-465.
2. Babatsikou F, Zavitsanou A. Epidemiology of hypertension in the elderly. Health Sci J. 2010;4(1):24-30.
3. Duprez DA. Systolic hypertension in the elderly: addressing an unmet need. Am J Med. 2008;121(3):179-184.
4. Tsiachris D, Tsioufs C, Dimitriadis K, et al. Relationship of ambulatory arterial stiffness index with blood pressure response to exercise in the early stages of hypertension. Blood Press Monit. 2010;15(3): 132-138.
5. Agabiti-Rosei E, Mancia G, O'Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50(1):154-160.
6. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103(9): 1245-1249.
7. Avolio A. Central aortic blood pressure and management of hypertension: confrmation of a paradigm shift? Hypertension. 2013; 62(6):1005-1007.
8. Williams B, Lacy PS; CAFE and ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol. 2009;54(8):705-713.
9. Jankowski P, Kawecka-Jaszcz K, Czarnecka D, et al; Aortic Blood Pressure and Survival Group. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension. 2008;51(4):848-855.
10. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50(1):197-203.
11. Roman MJ, Okin PM, Kizer JR, Lee ET, Howard B V, Devereux RB. Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. J Hypertens. 2010;28(2): 384-388.
12. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31(15):1865-1871.
13. Williams B, Lacy PS, Baschiera F, Brunel P, Dusing R. Novel description of the 24-hour circadian rhythms of brachial versus central aortic blood pressure and the impact of blood pressure treatment in a randomized controlled clinical trial: The Ambulatory Central Aortic Pressure (AmCAP) Study. Hypertension. 2013;61(6):1168-1176.
14. Izzo J, Weinberger M, Israel M, Hilkert R, Purkayastha D, Lee J, Black H. Aliskiren amlodipine com bination reduces central blood pressure more than amlodipine alone in African Americans with stage 2 hypertension: PP.5.171. J Hypertens. 2010;28:e99.
15. Ferdinand KC, Pool J, Weitzman R, Purkayastha D, Townsend R. Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. J Clin Hypertens. 2011;13(5):366-375.
16. Kanaoka T, Tamura K, Ohsawa M, et al. Effects of aliskiren-based therapy on ambulatory blood pressure profle, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients. J Clin Hypertens (Greenwich). 2012;14(8):522-529.
17. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens. 2010;24(9):600-608.
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classifcation, and stratifcation. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.
19. European Medicines Agency. ICH E6 (R1) Guideline for Good Clinical Practice. London: European Medicines Agency; 2002. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scien-tifc_guideline/2009/09/WC500002874.pdf. Accessed June 12, 2014.
20. Ishisone T, Koeda Y, Tanaka F, Sato K, Nagano M, Nakamura M. Comparison of utility of arterial stiffness parameters for predicting cardiovascular events in the general population. Int Heart J. 2013;54(3): 160-165.
21. Palmieri V, Devereux RB, Hollywood J, et al. Association of pulse pressure with cardiovascular outcome is independent of left ventricular hypertrophy and systolic dysfunction: the Strong Heart Study. Am J Hypertens. 2006;19(6):601-607.
22. Dusing R, Brunel P, Baek I, Baschiera F. Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study. J Hypertens. 2012;30(5): 1029-1040.
23. Bia D, Zocalo Y, Farro I, et al. Integrated evaluation of age-related changes in structural and functional vascular parameters used to assess arterial aging, subclinical atherosclerosis, and cardiovascular risk in Uruguayan adults: CUiiDARTE Project. Int J Hypertens. 2011;2011:587303.
24. Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockcroft JR, Wilkinson IB. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009;54(2):409-413.
25. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different anti-hypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17(2):118-123.
26. Black HR, Kribben A, Palacios FA, Bijarnia M, LaFlamme AK, Baschiera F. Aliskiren alone or in Combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension to provide QUick Intensive control of blood pressuRE: the ACQUIRE randomized, double blind study. J Clin Hypertension. 2010;12(12):917-926.
27. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. Journal of Human Hypertension. 2010;24:93-103.
28. Düsing R, Brunel P, Baek IY, Baschiera F. Sustained blood pressure lowering effect of aliskiren compared with telmisartan after a single missed-dose. J Clin Hypertens. 2013;15(1):41-47.
29. Bonadei I, Vizzardi E, D'Aloia A, Sciatti E, Raddino R, Metra M. Role of aliskiren on arterial stiffness and endothelial function in patients with primary hypertension. J Clin Hypertens (Greenwich). 2014;16(3):202-206.
30. Virdis A, Ghiadoni L, Qasem AA, et al. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. Eur Heart J. 2012;33(12):1530-1538.
31. Whaley-Connell A, Purkayastha D, Yadao A, Sowers JR. Central pressure and biomarker responses to renin inhibition with hydrochlorothiazide and ramipril in obese hypertensives: the ATTAIN study. Cardiorenal Med. 2011;1(1):53-66.
32. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-1225.
33. Jankowski P, Safar ME, Benetos A. Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. Curr Pharm Des. 2009;15(5):571-584.
34. Black HR, Weinberger MH, Purkayastha D, et al. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. J Clin Hypertens (Greenwich). 2011;13(8):571-581.
35. Sharman JE, Marwick TH, Gilroy D, et al; Value of Central Blood Pressure for GUIDing ManagEment of Hypertension Study Investigators. Randomized trial of guiding hypertension management using central aortic blood pressure compared with best-practice care: principal fndings of the BP GUIDE study. Hypertension. 2013;62(6): 1138-1145.
36. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol. 2013;75(1):79-92.